研究業績

2026年

Inoue R, Tajima K, Okuyama T, Sakai C, Kanno T, Zou M, Kyohara M, Matsunaga K, Tsuno T, Luo J, Ishida E, Horike SI, Hirano T, Arakawa N, Kin T, Shapiro AMJ, Terauchi Y, Obinata H, Hirano H, Shirakawa J.
Metformin suppresses β-cell apoptosis under ER stress by inhibiting protein translation. Metabolism. 2026;180:156607. doi:10.1016/j.metabol.2026.156607
Ishikawa R, Shirasaki M, Shiga K, Goda R, Kishino Y, Shimoda H, Hotta K, Kikuchi K, Inoue K, Saito M, Sugawara Y, Shigeyama T, Hamada R, Yamaguchi T, Murata K, Fujita H, Kakehi M, Yamamoto R, Takahara K, Arashida N, Yamamoto K, Mizuochi M, Koyama A, Yamato R, Iwasaki K, Fukuda S, Kawabata M, Ieki K, Uchiyama H, Une R, Yamaoka M, Tachiki H, Misawa T, Demizu Y, Saito Y, Kikura-Hanajiri R, Saito K.
Multi-laboratory development of bioanalytical methods for two cyclic peptides, cyclorasin9A5 and 3003pep. J Chromatogr B Analyt Technol Biomed Life Sci. 2026;1276:125020. doi:10.1016/j.jchromb.2026.125020
Saito K, Kagawa T, Tsuji K, Kumagai Y, Sato K, Sakisaka S, Sakamoto N, Aiso M, Hirose S, Mori N, Uraoka T, Takata K, Ogawa K, Mori K, Sato M, Nishiya T, Takamatsu K, Arakawa N, Izumi T, Kikura-Hanajiri R, Ohno Y, Saito Y, Takikawa H.
Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug-Induced Liver Injury. Hepatol Res. 2026;56:111-124. doi:10.1111/hepr.70043
Hattori N, Shibui Y, Tanaka Y, Saito Y.
Effect of blood microsampling (50 μL) on toxicological assessment in rats treated with tacrine, a drug known to have adverse effects that increase neutrophils. The Journal of Toxicological Sciences. 2026;51:19-30. doi:10.2131/jts.51.19

2025年

Zhao S, Jorge García CP, Li R, Kikura-Hanajiri R, Demizu Y, Tanaka Y, Ishii Y.
Enzymatic hydrolysis of ∆8-THC-O, ∆9-THC-O, 11-α-HHC-O, and 11-β-HHC-O by pooled human liver microsomes to generate ∆8-THC, ∆9-THC, 11-α-HHC, and 11-β-HHC. Forensic Toxicology. 2025;43:256-265. doi:10.1007/s11419-025-00719-2
Ogawara Y, Yokota NR, Yamada Y, Arakawa N, Sakamaki K, Kobayashi H, Kubota K, Kimura F, Mizushima T, Yamazaki E, Miyagi E.
Assessment of tissue factor pathway inhibitor 2 (TFPI2) as a novel serum marker for malignant tumors of the ovary before and after treatment: A case-control study. J Obstet Gynaecol Res. 2025;51(2):e16241. doi:10.1111/jog.16241
Yoshida A, Hashimoto Y, Saito Y, Kikura-Hanajiri R, Arakawa N.
Dataset for proteomic analysis of lung tissues from an oleic acid induced acute lung injury model rat. Journal of Proteome Data and Methods. 2025;7(4):1-3. doi:10.14889/jpdm.2025.0004
Yoshida A, Hashimoto Y, Akane H, Matsuyama S, Toyoda T, Ogawa K, Saito Y, Kikura-Hanajiri R, Arakawa N.
Analysis of Stratifin Expression and Proteome Variation in a Rat Model of Acute Lung Injury. Journal of Proteome Research. 2025;24(4):1941-1955. doi:10.1021/acs.jproteome.4c00980
Ishikawa R, Misawa T, Demizu Y, Saito Y, Kikura-Hanajiri R, Saito K.
Comprehensive in vitro evaluation of the inhibitory effects of relatively high molecular weight peptides on drug-drug interaction-associated four liver transporters and its association with physicochemical properties. Drug Metab Pharmacokinet. 2025;61:101055. doi:10.1016/j.dmpk.2025.101055
Ri M, Iida S, Saito K, Saito Y, Maruyama D, Asano A, Fukuhara S, Tsujimura H, Miyazaki K, Ota S, Fukuhara N, Negoro E, Kuroda J, Yoshida S, Ohtsuka E, Norifumi T, Tabayashi T, Takayama N, Saito T, Suzuki Y, Harada Y, Mizuno I, Yoshida I, Maruta M, Takamatsu Y, Katsuya H, Yoshimitsu M, Minami Y, Kanato K, Munakata W, Nagai H.
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1). Cancer Chemother Pharmacol. 2025;95(1):29. doi:10.1007/s00280-025-04752-1
Katsuyama M, Arakawa N, Yaoi T, Kimura E, Matsumoto M, Iwata K, Umemura A, Yabe-Nishimura C.
Clioquinol induces mitochondrial toxicity in SH-SY5Y neuroblastoma cells by affecting the respiratory chain complex IV and OPA1 dynamin-like GTPase. FEBS Lett. 2025;599(8):1135-1145. doi:10.1002/1873-3468.70033
Takano R, Ohoka N, Kurohara T, Arakawa N, Ohgane K, Inoue T, Yokoo H, Demizu Y.
Clozapine as an E3 Ligand for PROTAC Technology. ACS Med Chem Lett. 2025;16(2):258-262. doi:10.1021/acsmedchemlett.4c00500
Tanaka Y, Ono R, Ashiarai M, Sakurai A, Watanabe A, Tsuchimochi T, Hosoya Y, Hanajiri R, Inukai T, Hasegawa D.
The evaluation of the impact of NUDT15 variants on thiopurine metabolism in Japanese children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2025;95:50. doi:10.1007/s00280-025-04774-9
Tanaka Y, Hamano S, Ishii-Watabe A, Saito Y, Kikura-Hanajiri R.
Method validation and assessment of the biodistribution and shedding for adenovirus vector-based vaccine using qPCR and dPCR. Molecular Therapy Methods & Clinical Development. 2025;33:101549. doi:10.1016/j.omtm.2025.101549
Tanaka Y, Shimizu M, Saito Y, Yamazaki H.
Japanese medicinal drug labeling for use in the clinical setting as informed by pharmacogenomic data on cytochrome P450 enzymes obtained from in silico studies. Drug Metabolism and Pharmacokinetics. 2025;101:496. doi:10.1016/j.dmpk.2025.101496
Yamanaka M, Ushiki A, Tatsumi K, Gemma A, Hattori N, Tanaka Y, Saito Y, Hanaoka M.
Clinical characteristics of drug-induced interstitial pneumonia in Japan. Respiratory Investigation. 2025;63:524-531. doi:10.1016/j.resinv.2025.04.015
橋本玲奈，田中諒，福田理紗，持丸奈央子，綿貫沙織，壷井薫，松本正太朗，安齋葉月，仁科幸子，塚越絵里，吉田和恵．
市販点眼薬による小児中毒性表皮壊死症の1例．アレルギー．2025;74(5):285-289.
佐井君江，岡田美保子，小出大介．
医薬品識別情報の国際規格の国内導入及び安全性確保等への活用について．医薬品医療機器レギュラトリーサイエンス．2025;56:32-34.
孫雨晨．
siRNA治療における標的遺伝子に非依存的なフェロトーシス感作の増強．ファルマシア．2025;61(2):156.
Tanaka Y, Yokoi H, Kaji H, Urasaki Y, Nishidate M, Nitta SI, Watanabe K, Ishida T, Tanaka K, Komatsu R, Yoshida K, Saito K, Saito Y, Yamazaki H.
Current status of Imaging Mass Spectrometry in drug discovery and development: A survey highlighting technical challenges and future directions. Drug Metab Pharmacokinet. 2025;62:101485. doi:10.1016/j.dmpk.2025.101485
Shibata H, Nishimura K, Tsukagoshi E, Ishii-Watabe A, Saito Y, Yamada A, Masuoka A, Hirose W, Kawai S, Nanki T.
Evaluation of anti-drug antibodies against therapeutic monoclonal antibodies and related product in Japanese patients with rheumatoid arthritis and their clinical impact. European Journal of Pharmaceutical Sciences. 2025;216(2026):107357. doi: 10.1016/j.ejps.2025.107357
Osawa H, Saito K, Demizu Y.
Optimizing linker rigidity to improve intracellular behavior of PROTACs targeting hematopoietic prostaglandin D synthase. RSC Med Chem. 2025;16(10):4721-30. doi: 10.1039/d5md00396b.
Miyamoto M, Saito K, Yokoo H, Demizu Y.
Reductively activated CPP-PROTAC nanocomplexes enhance target degradation via efficient cellular uptake. RSC Chem Biol. 2025;6(11):1705-1710. doi: 10.1039/d5cb00196j.
Fujita M, Ito T, Inokuma A, Saito K, Hirano M, Yokoo H, Demizu Y.
Palindromic peptide foldamers: a strategy for structural stability and cellular uptake. Org Biomol Chem. 2025;23(24):5793-5797. doi: 10.1039/d5ob00430f.

2024年

Masuoka S, Nishio J, Yamada S, Saito K, Kaneko K, Kaburaki M, Tanaka N, Sato H, Muraoka S, Kawazoe M, Mizutani S, Furukawa K, Ishii-Watabe A, Kawai S, Saito Y, Nanki T.
Relationship Between the Lipidome Profile and Disease Activity in Patients with Rheumatoid Arthritis. Inflammation. 2024;47(4):1444-1458. doi: 10.1007/s10753-024-01986-8.
Sun Y, Saito K, Ushiki A, Abe M, Saito Y, Kashiwada T, Horimasu Y, Gemma A, Tatsumi K, Hattori N, Tsushima K, Takemoto K, Ishikawa R, Momiyama T, Matsuyama SI, Arakawa N, Akane H, Toyoda T, Ogawa K, Sato M, Takamatsu K, Mori K, Nishiya T, Izumi T, Ohno Y, Saito Y, Hanaoka M.
Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases. Respir Res. 2024;25:31. doi:10.1186/s12931-023-02653-6
Pineda Garcia JC, Li RS, Kikura-Hanajiri R, Tanaka Y, Ishii Y.
Timeframe Analysis of Novel Synthetic Cannabinoids Effects: A Study on Behavioral Response and Endogenous Cannabinoids Disruption. Int J Mol Sci. 2024;25:3083. doi:10.3390/ijms25063083
Adachi K, Ohyama K, Tanaka Y, Saito Y, Shimizu M, Yamazaki H.
Modeled Hepatic/Plasma Exposures of Fluvastatin Prescribed Alone in Subjects with Impaired Cytochrome P450 2C93 as One of Possible Determinant Factors Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database. Biol Pharm Bull. 2024;47(3):635-640.
Tsukagoshi E, Nakamura R, Kaniwa N, Sai K, Kikura-Hanajiri R, Matsunaga K, Abe R, Asada H, Saito Y.
Clinical profiles of Japanese patients with Stevens–Johnson syndrome/toxic epidermal necrolysis collected by a nationwide system from 2006 to 2023. Biol Pharm Bull. 2024;47(1):88-97. doi:10.1248/bpb.b23-00595
Fukunaga K, Tsukagoshi E, Kurata M, Mizukawa Y, Niihara H, Morita E, Watanabe Y, Yamaguchi Y, Watanabe H, Nakajima S, Nomura T, Kabashima K, Tohyama M, Azukizawa H, Asada H, Hasegawa A, Hama N, Ozeki T, Mashimo Y, Sekine A, Matsunaga K, Tanaka Y, Nakamura R, Abe R, Mushiroda T, Saito Y.
Differential effects of HLA-B15:11 and HLA-A31:01 on carbamazepine-induced cutaneous adverse reactions. J Invest Dermatol. 2024;144(4):908-911.e7. doi:10.1016/j.jid.2023.09.282
Saito K, Goda R, Arai K, Asahina K, Kawabata M, Uchiyama H, Andou T, Shimizu H, Takahara K, Kakehi M, Yamauchi S, Nitta SI, Suga T, Fujita H, Ishikawa R, Saito Y.
Interlaboratory evaluation of LC-MS-based biomarker assays. Bioanalysis. 2024;16:389-402. doi:10.4155/bio-2023-0173
Takahashi K, Hattori N, Yokoyama H, Jinno F, Ohtsuka H, Nakai K, Takumi A, Shibui Y, Yamaguchi K, Shimazaki T, Tanaka Y, Saito K, Kobayashi A, Saito Y.
Impact of microsampling on toxicological evaluation in rodent safety studies. J Appl Toxicol. 2024;44(1):118-128.
Hayashi Y, Sun Y.
Overcoming Challenges in Oligonucleotide Therapeutics Analysis: A Novel Nonion Pair Approach. J Am Soc Mass Spectrom. 2024;35(9):2034-2037. doi:10.1021/jasms.4c00270
Adachi K, Ohyama K, Tanaka Y, Murayama N, Shimizu M, Saito Y, Yamazaki H.
Modeled hepatic/plasma exposures of omeprazole prescribed alone in cytochrome P450 2C19 poor metabolizers are likely associated with hepatic toxicity reported in a Japanese adverse event database. Biol Pharm Bull. 2024;47(5):1028-1032. doi:10.1248/bpb.b24-00145
Hangai M, Kawaguchi T, Takagi M, Matsuo K, Jeon S, Chiang CWK, Dewan AT, de Smith AJ, Imamura T, Okamoto Y, Saito AM, Deguchi T, Kubo M, Tanaka Y, Ayukawa Y, Hori T, Ohki K, Kiyokawa N, Inukai T, Arakawa Y, Mori M, Hasegawa D, Tomizawa D, Fukushima H, Yuza Y, Noguchi Y, Taneyama Y, Ota S, Goto H, Yanagimachi M, Keino D, Koike K, Toyama D, Nakazawa Y, Nakamura K, Moriwaki K, Sekinaka Y, Morita D, Hirabayashi S, Hosoya Y, Yoshimoto Y, Yoshihara H, Ozawa M, Kobayashi S, Morisaki N, Gyeltshen T, Takahashi O, Okada Y, Matsuda M, Tanaka T, Inazawa J, Takita J, Ishida Y, Ohara A, Metayer C, Wiemels JL, Ma X, Mizutani S, Koh K, Momozawa Y, Horibe K, Matsuda F, Kato, Manabe A, Urayama KY.
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients. Haematologica. 2024;109(4):1247-1251. doi:10.3324/haematol.2023.282914
Shimizu M, Uehara S, Ohyama K, Nishimura H, Tanaka Y, Saito Y, Suemizu H, Yoshida S, Yamazaki H.
Pharmacokinetic Models Scaled-up from Humanized-liver Mouse Data Can Account for Drug Monitoring Results of Atomoxetine and Its 4-Hydroxylated and N-Demethylated Metabolites in Pediatric Patients Genotyped for Cytochrome P450 2D6. Drug Metab Dispos. 2024;52:35-43. doi:10.1124/dmd.123.001481
Fukunaga K, Tsukagoshi E, Nakamura R, Matsunaga K, Ozeki T, Watanabe H, Hasegawa A, Hama N, Kurata M, Mizukawa Y, Watanabe Y, Yamaguchi Y, Niihara H, Morita E, Asada H, Abe R, Saito Y, Mushiroda M.
Association of HLA-A11:01, HLA-B39:01 and HLA-B56:03 with salazosulfapyridine-induced cutaneous adverse drug reactions. J Allergy Clin Immunol Pract. 2024;12(5):1355-1358.e3. doi:10.1016/j.jaip.2024.02.041
Yokoo H, Osawa H, Saito K, Demizu Y.
Correlation between Membrane Permeability and the Intracellular Degradation Activity of Proteolysis-Targeting Chimeras. Chem Pharm Bull (Tokyo). 2024;72(11):961-965. doi: 10.1248/cpb.c24-00615.
Nishimura H, Hashii N, Yamamoto T, Sun Y, Miura T, Sato Y, Ishii-Watabe A.
Usefulness of Size-Exclusion Chromatography-Multi-Angle Light Scattering to Assess Particle Composition and Protein Impurities for Quality Control of Therapeutic Exosome Preparations. Pharmaceutics. 2024;16(12):1526. doi: 10.3390/pharmaceutics16121526
齊藤公亮，孫雨晨．
新規モダリティに関する生体試料中薬物濃度分析法バリデーション－核酸医薬品及び非天然型ペプチド医薬品－．医薬品医療機器レギュラトリーサイエンス．2024;55:24-34.
佐井君江．
医薬品コードの標準化：医療新時代に向けて．Precision Medicine. 2024;7:8-9.
佐井君江．
医薬品識別情報の国際規格：ISO IDMP． Precision Medicine. 2024;7:24-27.

過去の研究業績